New Rules to Accelerate Rare Disease Drug Development
This act introduces a new process to speed up the development and availability of drugs for rare diseases. It allows experts, drug companies, and patient organizations to discuss challenges and find innovative solutions together. Citizens suffering from rare conditions may see new treatment options become available more quickly.
Key points
Facilitates collaboration between experts, companies, and patients to accelerate research into rare disease drugs.
Mandatory meetings, at least four annually, focusing on different rare diseases to find the best treatment methods.
Increased transparency in drug approval, as the FDA will publicly disclose how expert meeting input was used.
Potentially faster access to new, effective therapies for individuals with rare conditions.
Introduced
Citizen Poll